Skip to main content
padlock icon - secure page this page is secure

Free Content A Retrospective Study of Acute Mountain Sickness on Mt. Kilimanjaro Using Trekking Company Data

Download Article:
 Download
(HTML 38.5 kb)
 
or
 Download
(PDF 666.9 kb)
 
Eigenberger P, Faino A, Maltzahn J, Lisk C, Frank E, Frank A, Loomis Z, Schroeder T, Strand M, Irwin D. A retrospective study of acute mountain sickness on Mt. Kilimanjaro using trekking company data. Aviat Space Environ Med 2014; 85:1125–9.

Background: High altitude illnesses (HAI) are a risk factor for any individual who is exposed to a significant increase in altitude. To learn more about the epidemiology of HAI, we sought to determine if health records from a commercial trekking company could provide novel data on the prevalence of HAI, as well as efficacy data regarding common HAI therapeutics. Methods: Health parameters from 917 tourists ascending Mt. Kilimanjaro over a 10-yr period were analyzed for meaningful data. Results: Of all subjects, 70% experienced at least one instance of a symptom related to HAI (headache, nausea, vomiting, diarrhea, or loss of appetite) during the trek. Acetazolamide was used at least once by 90% of subjects and, of those who used acetazolamide, 92% began taking it on day 1 of the ascent. Acetazolamide was found to improve oxygen saturation 1.2% above 9842.5 ft (3000 m). Dexamethasone use 12 h prior to ascending above 18,996 ft (5790 m) decreased the probability of a subject exhibiting at least one AMS symptom at that altitude. Discussion: The prevalence of AMS symptoms was not reduced by taking 2 extra days to reach the summit of Mt. Kilimanjaro. Prophylactic acetazolamide modestly improved oxygen saturation; however, it did not reduce symptoms. Therapeutic dexamethasone, especially at higher altitudes, was effective at reducing symptoms. We conclude that meaningful high altitude physiological data can be obtained from private trekking companies.

8 References.

No Supplementary Data.
No Article Media
No Metrics

Keywords: acetazolamide; acute mountain sickness; dexamethasone; epidemiology; high altitude

Document Type: Short Communication

Affiliations: University of Colorado, Denver, Anschutz Medical Campus, Aurora, CO, USA

Publication date: November 1, 2014

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more